SAN FRANCISCO--(BUSINESS WIRE)--Merriman Curhan Ford (NASDAQ: MERR) initiated equity research coverage today on Helix BioPharma (OTCQX: HXBPF | TSX: HBP) ($1.90), a Canadian biopharmaceutical company specializing in the field of cancer therapy, with a Buy rating.
